検索
AIM ImmunoTech Inc
AIMウォッチリストに追加
0.279USD
-0.017-5.84%
終値 06/30, 16:00（ET）15分遅れの株価
2.29M時価総額
損失額直近12ヶ月PER
詳細情報 AIM ImmunoTech Inc 企業名
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM ImmunoTech Incの企業情報
企業コードAIM
会社名AIM ImmunoTech Inc
上場日Jul 12, 1996
最高経営責任者「CEO」Equels (Thomas K)
従業員数21
証券種類Ordinary Share
決算期末Jul 12
本社所在地2117 Sw Highway 484
都市OCALA
証券取引所NASDAQ OMX – NASDAQ Basic Amex
国United States of America
郵便番号32801
電話番号13524487797
ウェブサイトhttps://aimimmuno.com/
企業コードAIM
上場日Jul 12, 1996
最高経営責任者「CEO」Equels (Thomas K)
AIM ImmunoTech Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
+39.13%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
+97.74%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+0.04%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
よくある質問
AIM ImmunoTech Incの上位5名の株主は誰ですか？
AIM ImmunoTech Incの上位5名の株主は以下のとおりです。Mr. Thomas K. Equels, Esq., J.D.
AIM ImmunoTech Inc（AIM）の株式を保有している機関の数はいくつですか？
2026Q1時点で、AIM ImmunoTech Incの株式を保有している機関は57社あり、保有株式の総市場価値は約105.74Kで、全体の1.30%を占めています。2025Q4と比較して、機関の持ち株は-74291.00増加しています。
